Seattle Genetics Company Updates |

Company Updates

  • We presented positive phase 3 ALCANZA clinical trial data for cutaneous T-cell #lymphoma w/ @TakedaOncology at #ASH16

  • We’re excited to be at #ASH16 to discuss new research in #Hodgkin #lymphoma, as part of 18 abstracts & 8 oral presentations.

    Seattle Genetics, Inc.: Investors & News : Press Release

    ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

  • We’re wearing red for #BCAM. Let’s make the future brighter for everyone touched by lymphoma #LightItRed

  • Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia
     -SGN-CD123A, A Novel ADC, Represents Seattle Genetics’ Second Clinical ADC Program Focused on AML-

    Seattle Genetics, Inc.: Investors & News : Press Release

    SGN-CD123A is a novel ADC targeted to CD123 utilizing Seattle Genetics' proprietary technology. CD123 is expressed across AML subtypes, including on leukemic stem cells, which are difficult to kill and may be responsible for high relapse rates even following intensive therapy.

  • We’re supporting Fred Hutch in the fight against cancer with our biggest Obliteride team ever! Check out our team page and join us in the fight.

    Please join me in the fight!

    Ride with me and tell others about Obliteride. Because while riding Obliteride might be hard, it's nothing compared to fighting cancer.

  • We’re proud to be #1 in Monster’s blog on 10 companies with awesome training & development programs

    10 Companies With Awesome Training And Development Programs |

    If you're looking for a career and not just any old job, set your sights on a company that invests in its employees by offering training and development programs. Research shows both companies and employees reap the benefits, including increased job satisfaction levels, internal promotion opportunities and better retention.

  • Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Investors & News

    The Phase 3 Study, Called CASCADE, will Evaluate 33A in Combination with Hypomethylating Agents in Older AML Patients- -Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial- -Additional 33A Phase 1 Data to be Featured in an Oral Presentation at the European Hematology Association Congress in June 2016- BOTHELL, Wash.--(BUSINESS WIRE)--May 25, 2016--Seattle Genetics, Inc.

  • CEO & George Washington University alum, Clay Siegall profiled in GWU's "Medicine + Health" - In a profile by his alma mater, Clay describes how he came to discover biomedical science and eventually start Seattle Genetics.

  • Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015

    Investors & News

    Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete Remission Rate- -Updated Phase 1 Data Evaluating ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Demonstrate a Three-Year Overall Survival Rate of 80 Percent, with Estimated Median Progression-Free Survival Not Yet Reached- ORLANDO, Fla.--(BUSINESS WIRE)--Dec.

  • Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015

    Investors & News

    Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy- -Data From Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for HL- -ADCETRIS Being Evaluated Broadly in more than 45 HL Clinical Trials- ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 7, 2015--Seattle Genetics, Inc.

Work at Seattle Genetics? Share Your Experiences

Seattle Genetics
  • Star
  • Star
  • Star
  • Star
  • Star
Click to Rate